The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer

Thomas G. Hopkins(Ovarian Cancer Action), Sarah P. Blagden(Churchill Hospital), Jennifer H. Steel(Imperial College London), Andrea J. Berman(University of Pittsburgh), Katrina Sweeney(Ovarian Cancer Action), Sadaf Ghaem‐Maghami(Hammersmith Hospital), Haonan Lu(Ovarian Cancer Action), Normala Abd Latip(Ovarian Cancer Action), Mona El‐Bahrawy(Al-Azhar University), Manuela Mura(Ovarian Cancer Action), Eric O. Aboagye(Imperial College London), Roni M. Lahr, Hiba A. Al-Ashtal(University of Pittsburgh), Justin Weir(Imperial College Healthcare NHS Trust)
Nucleic Acids Research
December 29, 2015
10.1093/nar/gkv1515
Cited by 164

Related Papers

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
|The Lancet|2019|223
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222
A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer
|Nature Communications|2019|215
La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs
|eLife|2017|201